Skip to main content
OpenTrials
Completed

NCT Number: NCT01664052

ESS505 Pre-hysterectomy Protocol

This study has been designed to evaluate an investigational model of the Essure System for Permanent Birth Control. The investigational device is designed to offer all the advantages of the currently approved device. In addition, the investigational device offers immediate, permanent contraception without a three-month waiting period or 90-day confirmation test. This study has been designed to evaluate the effectiveness of the investigational device in causing tubal occlusion from insert placement through three months of wearing.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Regina, Saskatchewan, Canada

Loading trial locations.

About this study

This study has previously been posted by Conceptus, Inc. (US).

After acquiring Conceptus, Inc., Bayer HealthCare AG (Germany) is the sponsor of the trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who are scheduled to undergo a Laparoscopically Assisted Vaginal Hysterectomy (LAVH), Total Abdominal Hysterectomy (TAH), Total Vaginal Hysterectomy (TVH), Total Laparoscopic Hysterectomy (TLH) with Bilateral Total Salpingectomy or Bilateral Salpingo-oophorectomy (BSO), or Laparoscopic Supracervical Hysterectomy (LSH)
  • Subjects who are 18 years of age and older
  • Subjects who are able and willing to provide written informed consent
  • Subjects who agree to use a contraceptive method following Essure placement until the hysterectomy procedure

Exclusion criteria

  • Subjects with bilateral proximal tubal occlusion
  • Subjects who have undergone fallopian tube sterilization
  • Subjects with known endometrial or myometrial pathology which is likely to prevent access to the fallopian tube ostia
  • Subjects who are post-menopausal
  • Subjects with pelvic inflammatory disease (PID)
  • Subjects with gynecologic malignancy
  • Pregnancy or suspected pregnancy
  • Delivery or termination of a pregnancy less than 6 weeks before Essure micro-insert placement
  • Known allergy to contrast media
  • Any general health condition that may represent, in the opinion of the Investigator, an increased potential risk associated with participation

Treatment and study plan

ESS505 (Essure, BAY1454033)

Device

Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.

ESS305 (Essure, BAY1454032)

Device

Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.

ESS505-A (Essure, BAY1454033)

Device

Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.

Primary outcomes

  1. Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation

    Time frame: 60 minutes after insert placement

    Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion.

  2. Number of Occluded Fallopian Tubes 30 Days Following Placement as Measured by an HSG Evaluation

    Time frame: 30 days after insert placement

    Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

  3. Number of Occluded Fallopian Tubes 60 Days Following Placement as Measured by an HSG Evaluation

    Time frame: 60 days after insert placement

    Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

  4. Number of Occluded Fallopian Tubes 90 Days Following Placement as Measured by an HSG Evaluation

    Time frame: 90 days after insert placement

    Hysterosalpingogram (HSG) is an x-ray of the uterus and fallopian tubes after the injection of a contrast material (dye). This test evaluates tubal occlusion. ESS505 and ESS505-A inserts are designed with the addition of an articulated hydrogel plug bonded to the distal portion of the insert with surgical grade adhesive and a nitinol support wire that remains inside the distal inner coil.

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Aug 14, 2012
Registry last updated
Aug 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.